Intracellular Signaling in Human Iridial Fibroblasts and Iridial Melanocytes in Response to Prostaglandins, Endothelin, Isoproterenol, and Other Pharmacological Agents

REFERENCES

• Camras CB. Mechanism of the prostaglandin-induced reduction of intraocular pressure in humans. Adv Prost Thromb Leukot Res. 1995;23:519–525.
   PubMedGoogle Scholar
• Stjernschantz J, Selen G, Sjoquist B, et al. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2α analogue. Adv Prost Thromb Leukot Res. 1995;23:513–518.
   PubMedGoogle Scholar
• Hellberg MR, Sallee V, McLaughlin M, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocular Pharmacol Ther. 2001;17:421–432.
   PubMed Web of Science ®Google Scholar
• Woodward DF, Krauss AHP, Chen J, et al. The pharmacology of bimatoprost (Lumigan™). Surv Ophthalmol. 2001;45(Suppl. 4):S337–S345.
   PubMedGoogle Scholar
• Taniguchi T, Haque MSR, Sugiyama K, et al. Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbit. J Ocular Pharmacol. 1996;12:489–498.
   Google Scholar
• Takagi Y, Nakajima T, Shimazaki A, et al. Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug. Exp Eye Res. 2004;78:767–776.
   PubMed Web of Science ®Google Scholar
• Davis TL, Sharif NA. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology. J Ocular Pharmacol Ther. 1999;15:323–336.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Davis TL, Williams GW. [3H]AL-5848 (9-β-[+]fluprostenol): Carboxylic acid of Travoprost (AL-6221), a novel FP-prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol. 1999;51:685–594.
   PubMedGoogle Scholar
• Ocklind A, Lake S, Wentzel P, et al. Localization of the prostaglandin F2α receptor messenger RNA and protein in the cynomolgus monkey eye. Invest Ophthalmol Vis Sci. 1996;37:716–726.
   PubMed Web of Science ®Google Scholar
• Wistrand PJ, Stjernschantz JW, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129–S138.
   Google Scholar
• Bito LZ. Prostaglandins: A new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol. 1997;41(Suppl. 22):S1–S14.
   Google Scholar
• Smith-Thomas L, Moustafa M, Spada CS, et al. Latanoprost-induced pigmentation in human iridial melanocytes is fibroblast dependent. Exp Eye Res. 2004;78:973–985.
   PubMed Web of Science ®Google Scholar
• Hu D-N Stjernschantz, J, McCormick SA. Effect of prostaglandin A2, E1, F2α and latanoprost on cultured human iridial melanocytes. Exp Eye Res. 2000;70:113–120.
   PubMedGoogle Scholar
• Hu D-N McCormick, SA, Orlow SJ, et al. Melanogenesis by human uveal melanocytes in vitro. Invest Ophthalmol Vis Sci. 1995;36:931–938.
   PubMedGoogle Scholar
• Hu D-N McCormick, SA, Woodward DF. A functional study on prostanoid receptors involved in cultured human iridial melanocytes stimulation. Exp Eye Res 2001;73:93–100.
   PubMedGoogle Scholar
• Griffin BW, Williams GW, Crider JY, et al. FP prostaglandin receptors mediating inositol phosphates generation and calcium mobilization in Swiss 3T3 cells: A pharmacological study. J Pharmacol Expt Ther. 1997;281:845–854.
   PubMed Web of Science ®Google Scholar
• Griffin BW, Magnino P, Pang I-H, et al. Pharmacological characterization of an FP prostaglandin receptor on rat vascular smooth muscle cells (A7r5) coupled to phosphoinositide turnover and intracellular calcium mobilization. J Pharmacol Expt Ther. 1998;286:411–418.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Xu SX, Williams GW, et al. Pharmacology of [3H]prostaglandin E1/[3H]prostaglandin E2 and [3H]prostaglandin F2α binding to EP3, and FP prostaglandin receptor binding sites in bovine corpus luteum: Characterization and correlation with functional data. J Pharmacol Exp Ther. 1998;286:1094–1102.
   PubMed Web of Science ®Google Scholar
• Crider JY, Xu SX, Sharif NA. Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: Comparison with binding data from human platelets. Prostagland Leukotri Essent Fatty Acids. 2001;65:253–258.
   PubMedGoogle Scholar
• Crider JY, Sharif NA. Adenylyl cyclase activity mediated by β2-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J Ocular Pharmacol Ther. 2002;18:221–230.
   PubMedGoogle Scholar
• Crider JY, Williams GW, Drace CD, et al. Pharmacological characterization of a serotonin receptor (5HT7) stimulating cAMP production in human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2003;44:4837–4844.
   PubMed Web of Science ®Google Scholar
• Stjernschantz JW, Albert DM, Hu D-N, et al. Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol. 2002;47(Suppl. 1):S162–S175.
   Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93–S105.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Crider JY, Husain S, et al. Human ciliary muscle responses to FP-class prostaglandin analogs: Phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocular Pharmacol Ther. 2003;19:437–455.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003;44:715–721.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocular Pharmacol Ther. 2002;18:313–324.
   PubMed Web of Science ®Google Scholar
• Sharif NA, Kelly CR, Crider JY, et al. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocular Pharmacol Ther. 2003;19:501–515.
   PubMed Web of Science ®Google Scholar
• Miceli F, Minicin F, Garcia P, et al. Endothelins enhance prostaglandin (PGE2 and PGF2α) biosynthesis and release by human luteal cells: Evidence of a new paracrine/autocrine regulation of luteal function. J Clin Endocrinol Metab. 2001;86:811–817.
   PubMedGoogle Scholar
• Deacon K, Knox AJ. Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cyclic adenosine-mono-phosphate (cAMP) pathways: role of phospholipase A2 (cPLA2)/cyclo-oxygenase-2 (COX-2)/prostacyclin receptor dependent autocrine loop. J Biol Chem. 2010;285:25913–25927.
   PubMed Web of Science ®Google Scholar
• Yousufzai SY, Ye Z, Abdel-Latif AA. Prostaglandin F2α and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species. Exp Eye Res. 1996;63:305–310.
   PubMed Web of Science ®Google Scholar
• Abdel-Latif AA. Phosphoinositides and arachidonic acid signaling systems in the mammalian iris. Prog Retinal Eye Res. 1995;14:75–107.
   Google Scholar
• Abdel-Latif AA. Minireview: Cross talk between cyclic nucleotides and polyphosphoinositide hydrolysis, protein kinases and contraction in smooth muscle. Exp Biol Med. 2001;226:153–163.
   Google Scholar
• Bergh K, Wentzel P, and Stjernschantz J. Production of prostaglandin E2 by iridial melanocytes exposed to latanoprost acid, A prostaglandin F2α analogue. J Ocular Pharmacol Ther. 2002;5:391–400.
   Google Scholar
• Milvae RA. Inter-relationships between endothelin and prostaglandin F2α in corpus luteum function. Rev Reproduction 2000;5:1–5.
   PubMedGoogle Scholar
• Doerr MD, Madhusudan GP, Rhinehart JD, et al. Effects of endothelin receptor type-A and type-B antagonists on prostaglandin F2alpha-induced luteolysis of the sheep corpus luteum. Biol Reproduction 2008;78:688–696.
   PubMedGoogle Scholar
• Takimoto M, Oda K, Sasaki Y, et al. Endothelin-1 receptor-mediated prostanoid secretion via autocrine and deoxyribonucleic acid synthesis via paracrine signaling in human bronchial epithelial cells. Endocrinol. 1996;137:4542–4550.
   PubMedGoogle Scholar
• Abdel-Latif AA, Yousufzai SYK, El-Mowafy AM, et al. Prostaglandins mediate the stimulatory effects of endothelin-1 on cyclic adenosine monophosphate accumulation in ciliary smooth muscle isolated from bovine, cat, and other mammalian species. Invest Ophthalmol Vis Sci. 1996;37:328–338.
   PubMedGoogle Scholar
• Bhattacherjee P, Smithson M, and Paterson CA. Generation of second messengers by prostanoids in the iris-sphincter and ciliary muscle of cows, cats and humans. Prostagland Leuko Essent Fatty Acids. 1997;56:443–449.
   PubMed Web of Science ®Google Scholar
• Hu D-N McCormick, SA, Orlow SJ, et al. Regulation of melanogenesis by human uveal melanocytes in vitro. Exp Eye Res. 1997;64:397–404.
   PubMedGoogle Scholar
• Hu D-N Woodward, WF, McCormick SA. Influence of autonomic neurotransmitters on human uvela melanocytes in vitro. Exp Eye Res. 2000;71:217–224.
   PubMedGoogle Scholar
• Somlyo AP, Wu X, Walker LA, et al. Pharmacomechanical coupling: The role of calcium, G-proteins, kinases and phosphatases. Rev Physiol Biochem Pharmacol. 1999;134:201–234.
   PubMedGoogle Scholar
• Langer SZ. Presynaptic autoreceptors regulating transmitter release. Neurochem Int. 2008;52:26–30.
   Google Scholar
• Starke K. Presynaptic autoreceptors in the third decade: Focus on alpha-2 adrenoceptors. J Neurochem. 2001;78:685–693.
   PubMedGoogle Scholar
• Harris LC, Awe SO, Opere CA, et al. [3H]-Serotonin release from bovine iris-ciliary body: Pharmacology of pre-junctional serotonin (5HT7) autoreceptors. Exp Eye Res. 2001;73:59–67.
   PubMed Web of Science ®Google Scholar
• Crider JY, Xu SX, Griffin BW, et al. Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2-, and IP-prostaglandin receptors in human ocular and other cell-types. Prostagland Leukotri Essential Fatty Acids. 1998;59:77–82.
   PubMedGoogle Scholar
• Sharif NA, Crider JY, Xu SX, et al. Affinities, selectivities, potencies and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther. 2000;293:321–328.
   PubMedGoogle Scholar
• Crider JY, Sharif NA. Functional pharmacological evidence for EP2 and EP4 prostanoid receptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells. J Ocular Pharmacol Ther. 2001;17:35–46.
   PubMed Web of Science ®Google Scholar
• Eglen RM, Michel AD, Sharif NA, et al. Pharmacological properties of the peptide, endothelin. Br J Pharmacol. 1989;97:1297–1307.
   PubMedGoogle Scholar
• Sharif NA, Whiting RL. Stimulation of inositol phosphate production in clonal HSDM1C1 cells by endothelins and sarafotoxin. Biochem Pharmacol. 1990;40:1928–1931.
   PubMedGoogle Scholar
• Hirose A, Azuma H, Tokoro T, et al. Endothelin-B receptors on suprachroidal melanocytes mediate an endothelin-1-induced increase in the intracellular calcium concentration of rabbit ocular suprachoroidal tissue. Curr Eye Res. 2007;32:585–591.
   PubMed Web of Science ®Google Scholar